Chemed Corporation

Chemed Corporation (CHE) Market Cap

Chemed Corporation has a market capitalization of $5.86B.

Price: $441.59

9.25 (2.14%)

Market Cap: 5.86B

NYSE · time unavailable

CEO: Kevin J. McNamara

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 1973-05-03

Website: https://www.chemed.com

Chemed Corporation (CHE) - Company Information

Market Cap: 5.86B|Sector: Healthcare

Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in two segments, VITAS and Roto-Rooter. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.

Analyst Sentiment

58%
Buy

From 4 Active Polls

1Y Forecast: $475.00

▲ +7.6% Potential Upside

Consensus Target Metrics

Low Bound

$475

Median

$475

High Bound

$475

Average

$475

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$475.00
▲ +7.57% Upside
Low Target
$475.00
8% Risk
Median Target
$475.00
8% Mid
High Target
$475.00
8% Max
Consensus
Hold
4 / 9 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)5,8625,1665,9876,5087,1128,9977,8699,0308,145
Enterprise Value ($M)6,0825,3866,0686,5207,0088,9687,8328,9398,069
Price to Earnings Ratio (P/E)23.2519.4819.5025.3333.8731.3521.7829.7928.73
Price/Earnings-to-Growth Ratio (PEG)6.858.4425.6828.873.9017.2325.47
Price to Sales Ratio (P/S)2.317.869.3710.4111.4913.9112.3014.9013.67
Price to Book Ratio (P/B)7.126.096.116.045.937.617.037.316.75
Price to Free Cash Flow Ratio (P/FCF)15.5472.6551.0998.5657.92462.2551.72117.31122.57
Enterprise Value to Sales (EV/Sales)8.199.4910.4311.3213.8612.2414.7513.54
Enterprise Value to EBITDA (EV/EBITDA)14.7153.0949.6264.0679.8080.0657.3976.3073.37
Debt to Equity Ratio0.530.280.160.130.120.120.130.120.12

CHE Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$441.59
Intrinsic Value$485.64
Market Alignment
Undervalued by 10.0%relative to calculated intrinsic value
9.00%
Exp: 4%4%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$0.45B
Perpetuity TV Value$8.49B
Discounted TV (PV)$3.58B
TV Weighting %60.0%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 CHEMED CORP (CHE) — Investment Overview

🧩 Business Model Overview

CHEMED is a two-segment operator with a shared emphasis on service delivery: (1) hospice and home-care services under VITAS, and (2) plumbing, drain, and related repair services under Roto-Rooter.

VITAS (Hospice/Home Care): CARE is delivered through clinician-staffed teams that manage patient episodes under payer rules (primarily government programs and managed care). The operational backbone is patient acquisition via referral and admissions, rapid care mobilization, and high-quality documentation/coding that supports reimbursement continuity.

Roto-Rooter (Plumbing Services): customers generate demand through emergency or scheduled repair needs. The company monetizes by dispatching technicians, installing/repairing plumbing systems, and providing repeat service where plumbing issues recur (drainage, water heaters, sewer lines). Profitability is driven by technician productivity, parts/service mix, and route density.

💰 Revenue Streams & Monetisation Model

VITAS: Hospice revenue is largely episode-based/per-diem driven with additional consideration for ancillary services and payer contract terms. Monetisation is less dependent on transaction-by-transaction selling and more dependent on sustained admission volume, payer mix, and care intensity consistent with reimbursement rules.

Roto-Rooter: Revenue is transactional, tied to service calls and job completion. Monetisation is influenced by average ticket size (repairs versus installs), repeat visit probability for recurring plumbing problems, and labor/parts economics.

Primary margin drivers: (1) labor productivity and staffing stability (clinical staffing for VITAS; technician utilization for Roto-Rooter), (2) payer reimbursement discipline and coding accuracy (VITAS), (3) service density and operational throughput (Roto-Rooter), and (4) working-capital discipline and cost controls across both segments.

🧠 Competitive Advantages & Market Positioning

CHEMED’s moats are best viewed as operating and switching-cost moats created by care continuity (healthcare) and service network density (home services), rather than a purely brand-driven advantage.

  • VITAS / Healthcare: Integrated episode management creates “care continuity” switching costs. Once a patient is in a hospice care pathway, continuity of clinicians, protocols, and documentation reduces friction for referrals and payer administration. The practical barrier is operational execution—staffing readiness, compliance, and care quality—rather than patient “switching” in the short term.
  • VITAS / Geographic density and referral relationships reduce unit costs. Dense coverage areas lower travel time and enable faster response times, which supports both clinical outcomes and cost per visit. The economics strengthen as an operator scales in a region.
  • Roto-Rooter / Dispatch and technician-route density reduce cost-to-serve. Service-network planning (dispatch, scheduling, and technician availability) improves labor utilization and reduces idle time. Faster mobilization and consistent service execution increase throughput and job completion rates.

Competitive benchmarking (explicit peer comparison):

  • Hospice/home-care peers: Amedisys, LHC Group, and Enhabit. These operators compete on regional coverage, admission growth, staffing model, and payer contract terms. CHEMED’s positioning emphasizes operational execution and dense coverage through VITAS, aiming to sustain care continuity economics.
  • Plumbing/drain-service peers: Mr. Rooter, Benjamin Franklin Plumbing, and a large set of local independent plumbing contractors. Competition centers on technician availability, responsiveness, and pricing/quality of repair work. CHEMED’s Roto-Rooter model differentiates through service-network utilization and standardized dispatch/operations.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, CHEMED’s growth outlook is supported by several structural demand forces:

  • Aging demographics and higher incidence of chronic/advanced illness drive a larger population eligible for hospice and home-care services.
  • Site-of-care substitution: continued shift toward care delivered at home rather than in institutional settings supports demand for hospice and home-care providers with strong operational capability.
  • Care model capacity discipline: providers that can staff and comply efficiently capture patient volume without sacrificing documentation quality—an advantage during periods of labor market tightness.
  • Housing stock and infrastructure repair cycle underpin recurring plumbing service needs, including drain and sewer-related maintenance as systems age.
  • Utilization of service networks: as demand fluctuates, operators with dense coverage and efficient dispatch can protect labor productivity and preserve unit economics.

⚠ Risk Factors to Monitor

  • Regulatory and reimbursement pressure (VITAS): Medicare/managed-care rule changes, coding/documentation requirements, and reimbursement dynamics can affect margins and admission throughput.
  • Staffing constraints and wage inflation (both segments): clinical labor shortages can impair response times and care delivery; technician labor costs can compress service margins.
  • Service execution and quality/regulatory compliance (VITAS): documentation accuracy, billing compliance, and clinical quality oversight are core to reimbursement stability.
  • Demand cyclicality (Roto-Rooter): plumbing service volumes are less discretionary than remodeling but can still be influenced by consumer and commercial spending patterns.
  • Competitive intensity: regional entrants and contract competition can pressure pricing or increase customer acquisition costs.
  • Concentration and operational leverage: both segments rely on workforce productivity; operational missteps can have outsized impact on cash generation.

📊 Valuation & Market View

CHEMED typically trades in a framework investors use for service-heavy, cash-generative operating companies:

  • EV/EBITDA and earnings quality: the market places weight on sustainable cash flow, normalized margins, and resilience of operating costs.
  • Segment mix considerations: hospice/home-care economics often receive valuation support when investors view reimbursement stability and care continuity as durable. Home services are evaluated on labor productivity, unit economics, and demand durability.
  • Multiple expansion drivers: margin durability, stable admissions/volume, disciplined operating costs, and credible staffing economics can expand valuation. Multiple compression can follow reimbursement uncertainty, adverse mix, or sustained labor cost pressure.

🔍 Investment Takeaway

CHEMED’s long-term thesis rests on operational moats—not just demand tailwinds. In healthcare, VITAS benefits from care continuity and regional density that support unit-cost advantages and patient pathway stability. In home services, Roto-Rooter’s advantages derive from dispatch-driven network density and labor productivity. The combined model targets resilient cash generation through episode-based care economics and throughput-focused service operations, with key risks centered on reimbursement policy and workforce availability.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for CHE.

zacks.com2026-05-25

AVAH vs. CHE: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Aveanna Healthcare (AVAH) or Chemed (CHE). But which of these two stocks is more attractive to value investors?

seekingalpha.com2026-05-20

Chemed Corporation (CHE) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Chemed Corporation (CHE) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

globenewswire.com2026-05-18

Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend

CINCINNATI, May 18, 2026 (GLOBE NEWSWIRE) -- Stockholders of Chemed Corporation (NYSE: CHE) today elected a slate of nine directors at the Company's 2026 annual stockholders' meeting. Stockholders ratified the continuation of PricewaterhouseCoopers LLP as the Company's independent accountants for 2026.

globenewswire.com2026-05-18

Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend

CINCINNATI, May 18, 2026 (GLOBE NEWSWIRE) -- Stockholders of Chemed Corporation (NYSE: CHE) today elected a slate of nine directors at the Company's 2026 annual stockholders' meeting.

seekingalpha.com2026-05-13

Chemtrade Logistics Income Fund (CHE.UN:CA) Q1 2026 Earnings Call Prepared Remarks Transcript

Chemtrade Logistics Income Fund (CHE.UN:CA) Q1 2026 Earnings Call Prepared Remarks Transcript

globenewswire.com2026-05-13

Chemed Corporation to Present at the 2026 RBC Global Healthcare Conference

CINCINNATI, May 13, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026, at approximately 8:30 a.m. (ET) at The InterContinental New York Barclay Hotel in New York City.

seekingalpha.com2026-05-12

Chemed Corporation (CHE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Chemed Corporation (CHE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com2026-05-12

Chemtrade Logistics Income Fund (CHE.UN:CA) Q1 2026 Earnings Call Transcript

Chemtrade Logistics Income Fund (CHE.UN:CA) Q1 2026 Earnings Call Transcript

globenewswire.com2026-05-05

Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2026

CINCINNATI, May 05, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Bank of America Securities 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:00 PM (PDT) at the Encore at the Wynn Las Vegas. The presentation will be webcast live and can be accessed, along with the presentation materials, through the Chemed website at www.chemed.com (Investor Relations).

zacks.com2026-04-27

CHE Stock Up Following Q1 Earnings & Revenue Beat, Margins Down

Chemed stock jumps after Q1 earnings and revenues beat estimates despite margin contraction and mixed segment performance across VITAS and Roto-Rooter.

defenseworld.net2026-04-27

Chemed (NYSE:CHE) & LifeStance Health Group (NASDAQ:LFST) Financial Comparison

Chemed (NYSE: CHE - Get Free Report) and LifeStance Health Group (NASDAQ: LFST - Get Free Report) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability. Institutional and Insider Ownership 95.9% of Chemed

defenseworld.net2026-04-26

Chemed Corporation $CHE Shares Bought by Cwm LLC

Cwm LLC boosted its holdings in shares of Chemed Corporation (NYSE: CHE) by 88.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,084 shares of the company's stock after purchasing an additional 1,914 shares during the period. Cwm LLC's holdings in

defenseworld.net2026-04-26

Abacus FCF Advisors LLC Acquires New Holdings in Chemed Corporation $CHE

Abacus FCF Advisors LLC bought a new position in shares of Chemed Corporation (NYSE: CHE) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 13,871 shares of the company's stock, valued at approximately $5,935,000. Abacus FCF Advisors LLC owned 0.10% of Chemed at

seekingalpha.com2026-04-24

Chemed Corporation (CHE) Q1 2026 Earnings Call Transcript

Chemed Corporation (CHE) Q1 2026 Earnings Call Transcript

zacks.com2026-04-23

Chemed (CHE) Beats Q1 Earnings and Revenue Estimates

Chemed (CHE) came out with quarterly earnings of $5.65 per share, beating the Zacks Consensus Estimate of $5.17 per share. This compares to earnings of $5.63 per share a year ago.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"Over the last four quarters, Chemed Corporation (CHE) reported revenue growth of 1.17% YoY to $657.5 million for Q1 2026 compared to $646.9 million in Q1 2025. However, on a QoQ basis, revenue rose more significantly by 2.84% from Q4 2025. Net income for Q1 2026 was $66.3 million, a 7.56% decrease YoY from $71.8 million in Q1 2025, and an 11.37% decrease QoQ. Earnings per share shrank from $4.91 to $4.85 over the year, signaling slight margin contraction despite stable overall net income. The total assets slightly declined from $1.73 billion in Q1 2025 to $1.54 billion in Q1 2026, while net debt increased significantly, reflecting higher financial leverage. The company maintained steady quarterly dividend payouts, though the dividend yield remains low due to the low stock price. Total shareholder return was negatively impacted by an over 33% drop in share price over the past year, indicating a challenging market environment. Despite steady revenue gains, Chemed faces profitability pressure and a steep price decline, reflected in a PE Ratio of 19.48, lower than previous quarters but still suggesting mixed investor sentiment."

Revenue Growth

Positive

Revenue grew YoY by 1.17% and QoQ by 2.84%, indicating continued, albeit slow, expansion.

Profitability

Caution

Margins contracted as YoY net income fell 7.56% with EPS slightly down, reflecting profitability pressures.

Cash Flow Quality

Caution

Net income fluctuations and increased financial leverage suggest moderate cash flow volatility; dividend remains safe.

Leverage & Balance Sheet

Fair

Total assets declined, and net debt increased, indicating higher leverage and potential balance sheet stress.

Shareholder Returns

Neutral

With a one-year price decline over 33%, total shareholder return was poor despite consistent dividends.

Analyst Sentiment & Valuation

Fair

Current price of $384.61 below target consensus of $475, indicates undervaluation yet potential for appreciation.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Q1 2026 shows a split at Chemed: VITAS outperformed with ADC growth and margin support, while Roto-Rooter faced profitability pressure from higher internet marketing costs and weather disruption. VITAS net revenue rose 3.1% to $420M, aided by days of care (+2.2%) and reimbursement rate (+~2.6%), despite revenue drag from acuity mix (-120 bps) and Medicare Cap/contra items (-~47 bps). Importantly, VITAS avoided Medicare Cap billing limitation in Florida for 2026 expectations (none anticipated), and added $32.5M to Medicare Cap cushion. Roto-Rooter delivered improved residential core revenue (first increase since Q4 2022) and strong lead metrics (paid leads +18.7%), but adjusted EBITDA fell 9.6% with margins down 218 bps, driven mainly by elevated Google marketing spend. Guidance was raised for VITAS ADC/revenue/EBITDA margin (excluding Medicare Cap) while Roto-Rooter EBITDA margin was trimmed due to persistent marketing cost headwinds.

AI IconGrowth Catalysts

  • VITAS ADC growth via accelerated admissions from nonhospital preadmission locations while maintaining high hospital-based emissions; admissions +6.9% YoY to 19,394
  • Florida combined program added $32.5 million to Medicare Cap cushion in Q1 2026 (management confidence cap issue behind them; normalized growth)
  • Roto-Rooter residential plumbing and residential sewer/drain revenue both increased YoY for first time since Q4 2022; total leads +3.3% and paid leads +18.7%
  • Roto-Rooter centralization of water restoration billing/collections improving collections and reducing write-offs (write-offs improved by $1.5 million YoY)

Business Development

  • Roto-Rooter repurchased franchise territories/assets: San Francisco, CA and Fort Worth, TX (2 separate transactions; aggregated purchase price ~$20.6 million); adds ~$5.0M to ~$5.5M of revenue for remainder of 2026, immediately accretive
  • Added 18 new commercial business managers in Q1 2026 (commercial revenue up ~10% for 13 branches with managers coming into 2026)

AI IconFinancial Highlights

  • VITAS net revenue $420M (+3.1% YoY): days of care +2.2% and Medicare reimbursement rate +~2.6%
  • VITAS revenue headwinds: acuity mix negatively impacted by 120 bps; Medicare Cap and other contra revenue changes negatively impacted by ~47 bps
  • VITAS Medicare Cap billing limitation accrual: $2.4M in Q1 2026; management expects $0 Medicare Cap billing limitation for Florida combined program in 2026 fiscal period
  • VITAS average revenue per day $210.62 (+146 bps YoY improvement); high acuity days 2.3% of total days (-28 bps YoY)
  • VITAS adjusted EBITDA excluding Medicare Cap: $70.8M (+0.6% YoY); adjusted EBITDA margin excluding Medicare Cap 16.8%
  • Roto-Rooter adjusted EBITDA $53.5M (-9.6% YoY); adjusted EBITDA margin 22.5% (-218 bps YoY) mainly due to elevated internet/Google marketing costs
  • Roto-Rooter core services improvement: residential plumbing and residential sewer/drain revenue increased; lead mix shifted to paid ads generating 53.4% of leads vs 46.5% in Q1 2025
  • Q1 2026 weather disruption: unusual ice/snow caused service disruptions across 24 branches for ~5 days; estimated net revenue loss $3M-$4M
  • Weather disruption also tied to marketing overrun: marketing costs +$3M YoY (vs guidance framework) with ~$1M expected to be weather-related and excluded from run-rate; full guidance margin change attributed to adding ~$1M/quarter marketing for next 3 quarters

AI IconCapital Funding

  • Roto-Rooter franchise territory/asset repurchases: aggregated ~$20.6M for San Francisco, CA and Fort Worth, TX (immediately accretive; ~$5.0M-$5.5M revenue contribution for remainder of 2026)
  • No explicit consolidated buyback amount, debt level, or cash runway disclosed in the provided transcript excerpt

AI IconStrategy & Ops

  • VITAS: transition to balance short-stay vs long-stay patient mix; added ADC through accelerated admissions while keeping hospice labor costs below budget
  • VITAS: average length of stay 102.7 days vs 118.7 in Q1 2025; median length of stay 15 days (down 1 day YoY); new starts Marian/Pasco/Pinellas combined 526 admissions in Q1; Manati County opening targeted late Q2 or early Q3 with an aggressive approach
  • Roto-Rooter: residential core service momentum supported by lead generation improvements; paid lead share increased to 53.4% from 46.5%
  • Roto-Rooter: centralized water restoration billing/collections continues; during transition, average revenue per water restoration job declined ~13% in Q1 with expectation to improve through the year
  • Roto-Rooter: internet marketing/Google algorithm changes driving paid lead reliance; management indicated continued “tough sledding” on natural/free search short term and expect marketing cost run-rate to stay elevated

AI IconMarket Outlook

  • 2026 guidance update (full year, excluding Medicare Cap where noted): VITAS full-year ADC growth range increased to 4.5% to 5.5% (from original 3.5% to 4%)
  • 2026 guidance update (full year, excluding impact of Medicare Cap): anticipated revenue growth revised to 6.5% to 7.5% (from original guidance 5.5% to 6.5%)
  • 2026 adjusted EBITDA margin (excluding Medicare Cap): revised to 18.0% to 18.5% (from original 17.5% to 18.5%)
  • 2026 Roto-Rooter: anticipated revenue growth remains unchanged at 3% to 3.5%; estimated adjusted EBITDA margin lowered slightly to 21.5% to 22.5% (from original 22.5% to 23%) due to elevated marketing costs expected to persist above prior assumptions
  • 2026 earnings per diluted share (adjusted; excluding specified noncash/discrete items): $20.00 to $24.75; midpoint implies +13% vs 2025 adjusted EPS of $21.55; effective corporate tax rate on adjusted earnings assumed 24.5%; diluted share count 13.6M

AI IconRisks & Headwinds

  • VITAS: Medicare Cap/revenue contra headwinds persist (Q1 acuity mix -120 bps; Medicare Cap/contra changes -~47 bps); $2.4M Medicare Cap billing limitation accrual in Q1
  • VITAS: hospice fraud/waste enforcement campaign could increase scrutiny in certain markets (discussion referenced California hospice concerns and CMS enforcement climate; management focused on protecting legitimate access)
  • Roto-Rooter: elevated internet/Google marketing costs drove -218 bps YoY decline in adjusted EBITDA margin; natural/free search visibility pressured by Google algorithm changes
  • Roto-Rooter: macro/weather and service disruption risks (Q1 net revenue loss $3M-$4M due to ice/snow across 24 branches)
  • Roto-Rooter: water restoration monetization transition risk—average revenue per water restoration job -~13% in Q1 during centralized billing rollout
  • Roto-Rooter: independent contractor revenue -3.3% YoY; contractor segment needs mitigation to regain growth trajectory

Q&A: Analyst Interest

  • Topic: VITAS margin drivers and capacity plan for ADC growth: Management said margins benefited from averaging ~100 FTEs below budget while serving higher ADC, but it’s not sustainable. They planned to add capacity from 30–40 FTEs/month to ~60 FTEs/month for the rest of 2026 to match (or exceed) ADC targets.
  • Topic: Roto-Rooter marketing cost run-rate, Google visibility dynamics, and Q2 trend confirmation: Management explained marketing costs proxy Google costs; despite leads +3% YoY, natural/free leads were down ~16% after Google algorithm changes. Paid clicks rose >18%, requiring higher bid spend. They expected “tough sledding” on natural search and continued elevated marketing costs into Q2.
  • Topic: Roto-Rooter guidance bridge and collection/billing impact from centralized model: Management confirmed Q1 was slightly better than a prior year collection/overhaul expectation, but improvements partly reflected billing fewer jobs. They expect both collection and revenue-per-job to improve as centralized employees gain experience and finalize the transition, while acquisitions add some revenue offsetting other headwinds.

Sentiment: MIXED

Note: This summary was synthesized by AI from the CHE Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for CHE.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (CHE)

© 2026 Stock Market Info — Chemed Corporation (CHE) Financial Profile